Clinical Trial Update: A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating atezolizumab, bevacizumab, and ADI-PEG 20 for locally advanced or metastatic hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN